Your browser doesn't support javascript.
loading
Characterization of a KDM5 small molecule inhibitor with antiviral activity against hepatitis B virus.
Gilmore, Sarah A; Tam, Danny; Cheung, Tara L; Snyder, Chelsea; Farand, Julie; Dick, Ryan; Matles, Mike; Feng, Joy Y; Ramirez, Ricardo; Li, Li; Yu, Helen; Xu, Yili; Barnes, Dwight; Czerwieniec, Gregg; Brendza, Katherine M; Appleby, Todd C; Birkus, Gabriel; Willkom, Madeleine; Kobayashi, Tetsuya; Paoli, Eric; Labelle, Marc; Boesen, Thomas; Tay, Chin H; Delaney, William E; Notte, Gregory T; Schmitz, Uli; Feierbach, Becket.
Affiliation
  • Gilmore SA; Gilead Sciences, Inc., Foster City, California, United States America.
  • Tam D; Gilead Sciences, Inc., Foster City, California, United States America.
  • Cheung TL; Gilead Sciences, Inc., Foster City, California, United States America.
  • Snyder C; Gilead Sciences, Inc., Foster City, California, United States America.
  • Farand J; Gilead Sciences, Inc., Foster City, California, United States America.
  • Dick R; Gilead Sciences, Inc., Foster City, California, United States America.
  • Matles M; Gilead Sciences, Inc., Foster City, California, United States America.
  • Feng JY; Gilead Sciences, Inc., Foster City, California, United States America.
  • Ramirez R; Gilead Sciences, Inc., Foster City, California, United States America.
  • Li L; Gilead Sciences, Inc., Foster City, California, United States America.
  • Yu H; Gilead Sciences, Inc., Foster City, California, United States America.
  • Xu Y; Gilead Sciences, Inc., Foster City, California, United States America.
  • Barnes D; Gilead Sciences, Inc., Foster City, California, United States America.
  • Czerwieniec G; Gilead Sciences, Inc., Foster City, California, United States America.
  • Brendza KM; Gilead Sciences, Inc., Foster City, California, United States America.
  • Appleby TC; Gilead Sciences, Inc., Foster City, California, United States America.
  • Birkus G; Gilead Sciences, Inc., Foster City, California, United States America.
  • Willkom M; Gilead Sciences, Inc., Foster City, California, United States America.
  • Kobayashi T; Gilead Sciences, Inc., Foster City, California, United States America.
  • Paoli E; Gilead Sciences, Inc., Foster City, California, United States America.
  • Labelle M; EpiTherapeutics ApS, Copenhagen, Denmark.
  • Boesen T; EpiTherapeutics ApS, Copenhagen, Denmark.
  • Tay CH; Novo Nordisk A/S, Bagsvaerd, Denmark.
  • Delaney WE; Gilead Sciences, Inc., Foster City, California, United States America.
  • Notte GT; Gilead Sciences, Inc., Foster City, California, United States America.
  • Schmitz U; Gilead Sciences, Inc., Foster City, California, United States America.
  • Feierbach B; Gilead Sciences, Inc., Foster City, California, United States America.
PLoS One ; 17(12): e0271145, 2022.
Article in En | MEDLINE | ID: mdl-36477212
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hepatitis B virus / Hepatitis B, Chronic Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2022 Document type: Article Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hepatitis B virus / Hepatitis B, Chronic Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2022 Document type: Article Country of publication: Estados Unidos